CalciMedica Announces Upcoming Plenary Presentation at the 30th International AKI & CRRT Conference
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, has announced an upcoming plenary presentation at the 30th International AKI & CRRT Conference in San Diego.
The company's Chief Medical Officer, Dr. Sudarshan Hebbar, will present on 'The Role of ORAI-1 in AKI' during the 'Bench to Bedside: Translating Discoveries to Clinical Care' session on March 3, 2025, at 10:35 AM PT.
CalciMedica (Nasdaq: CALC), un'azienda biofarmaceutica in fase clinica specializzata in terapie di inibizione dei canali CRAC per malattie infiammatorie e immunologiche, ha annunciato una prossima presentazione plenaria alla 30ª Conferenza Internazionale AKI & CRRT a San Diego.
Il Chief Medical Officer dell'azienda, Dr. Sudarshan Hebbar, presenterà su 'Il Ruolo di ORAI-1 nell'AKI' durante la sessione 'Dalla panca al letto: Tradurre le scoperte nella cura clinica' il 3 marzo 2025, alle 10:35 AM PT.
CalciMedica (Nasdaq: CALC), una compañía biofarmacéutica en etapa clínica especializada en terapias de inhibición de canales CRAC para enfermedades inflamatorias e inmunológicas, ha anunciado una próxima presentación plenaria en la 30ª Conferencia Internacional AKI & CRRT en San Diego.
El Director Médico de la compañía, Dr. Sudarshan Hebbar, presentará sobre 'El Papel de ORAI-1 en AKI' durante la sesión 'De la banca a la cama: Traduciendo descubrimientos a la atención clínica' el 3 de marzo de 2025, a las 10:35 AM PT.
CalciMedica (Nasdaq: CALC)는 염증 및 면역 질환을 위한 CRAC 채널 억제 치료법을 전문으로 하는 임상 단계의 생명공학 회사로, 샌디에이고에서 열리는 제30회 국제 AKI & CRRT 컨퍼런스에서 곧 있을 전체 발표를 발표했습니다.
회사의 최고 의료 책임자인 Sudarshan Hebbar 박사는 2025년 3월 3일 오전 10시 35분 PT에 '벤치에서 침대까지: 발견을 임상 치료로 전환하기' 세션에서 'AKI에서 ORAI-1의 역할'에 대해 발표할 예정입니다.
CalciMedica (Nasdaq: CALC), une entreprise biopharmaceutique en phase clinique spécialisée dans les thérapies d'inhibition des canaux CRAC pour les maladies inflammatoires et immunologiques, a annoncé une prochaine présentation plénière lors de la 30e Conférence Internationale AKI & CRRT à San Diego.
Le directeur médical de l'entreprise, Dr. Sudarshan Hebbar, présentera sur 'Le Rôle de ORAI-1 dans l'AKI' lors de la session 'De la paillasse au chevet : Traduire les découvertes en soins cliniques' le 3 mars 2025, à 10h35 PT.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf CRAC-Kanal-Inhibitionstherapien für entzündliche und immunologische Erkrankungen spezialisiert hat, hat eine bevorstehende Plenarvorstellung auf der 30. Internationalen AKI & CRRT-Konferenz in San Diego angekündigt.
Der Chief Medical Officer des Unternehmens, Dr. Sudarshan Hebbar, wird am 3. März 2025 um 10:35 Uhr PT während der Sitzung 'Von der Bank zum Bett: Entdeckungen in die klinische Versorgung übersetzen' über 'Die Rolle von ORAI-1 bei AKI' sprechen.
- None.
- None.
Details for the presentation are as follows:
Presentation Title: The Role of ORAI-1 in AKI
Presenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica
Session Title: Plenary 2: Bench to Bedside: Translating Discoveries to Clinical Care
Session Date and Time: Monday, March 3, 10:35-10:55 a.m. PT
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in
Contact Information
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-upcoming-plenary-presentation-at-the-30th-international-aki--crrt-conference-302379681.html
SOURCE CalciMedica, Inc.
FAQ
When is CalciMedica (CALC) presenting at the 30th International AKI & CRRT Conference?
What is the topic of CalciMedica's (CALC) presentation at the AKI & CRRT Conference 2025?
Who will be presenting for CalciMedica (CALC) at the 2025 AKI & CRRT Conference?
What type of therapies is CalciMedica (CALC) developing?
